title: ZRX1, the first EGFR inhibitor-capecitabine based combi-molecule, requires carboxylesterase-mediated hydrolysis for optimal activity.
abstract: Capecitabine, an orally available prodrug of 5-FU, requires activation by carboxylesterase (CES) enzymes present in the liver to generate 5'-deoxy-5-flurocytidine ribose (5'-DFCR). The deamination of the latter by cytidine deaminase gives 5'-deoxy-5-fluorouridine ribose (5'-DFUR). Finally, the conversion of 5'-DFUR to the cytotoxic drug 5-FU, occurs primarily in the tumour and is catalyzed by thymidine phosphorylase (TP). Accordingly, it was surmised that events associated with an increase of TP levels should enhance the potency of capecitabine and its metabolites. EGFR inhibition was found to be one such event. The observed synergy between gefitinib and 5'-DFUR has inspired the design of single molecules capable of acting as prodrugs of both an EGFR inhibitor and 5-FU. Here, we report on the synthesis and characterization of one such molecule, ZRX1, that consists of an acetylated 5'-DFCR moiety linked to a quinazoline inhibitor of EGFR through an alkyl dicarbamate spacer that requires CES activation to generate the two active metabolites. Our results showed that ZRX1 was ineffective as an intact molecule. However, when CES was present, ZRX1 induced an increase in EGFR inhibition, TP expression, DNA damage and apoptosis. ZRX1 was, at least, 3-fold more potent than capecitabine and 5'-DFUR and recapitulated the effects of the combination treatments. LC-MS analysis showed that in the presence of CES, ZRX1 is metabolized into a mixture of bioactive quinazoline derivatives and 5'-DFCR derived metabolites. Our results in toto, suggest that capecitabine-based EGFR targeting combi-molecules of the same type than ZRX1, have the potential to induce stronger growth inhibitory potency than capecitabine, 5'-DFUR or single EGFR inhibitors and equivalent potency when compared with combinations of EGFR inhibitors + 5'-DFUR.
authors: Maria
authors: M
authors: Ait-Tihyaty
authors: Zakaria
authors: Z
authors: Rachid
authors: Anne-Laure
authors: AL
authors: Larroque-Lombard
authors: Bertrand J
authors: BJ
authors: Jean-Claude
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D000069287:Capecitabine; D002219:Carbamates / Q000494:pharmacology*; D043182:Carboxylesterase / Q000378:metabolism*; D045744:Cell Line, Tumor; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000378:metabolism; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D006868:Hydrolysis; D051379:Mice; D008807:Mice, Inbred BALB C; D009369:Neoplasms / Q000378:metabolism*; D011799:Quinazolines / Q000494:pharmacology*; D013939:Thymidine Phosphorylase / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D002219:Carbamates; D011799:Quinazolines; C000589324:ZRX1 compound; D003841:Deoxycytidine; D000069287:Capecitabine; D013939:Thymidine Phosphorylase; D066246:ErbB Receptors; D043182:Carboxylesterase; D005472:Fluorouracil
references: Biochemistry. 1969 Oct;8(10):3879-89
references: 4981346
references: Clin Cancer Res. 1998 Apr;4(4):1013-9
references: 9563897
references: J Toxicol Sci. 2011 Aug;36(4):411-22
references: 21804305
references: Molecules. 2008 Feb 18;13(2):412-31
references: 18305428
references: Br J Cancer. 2002 Mar 4;86(5):819-27
references: 11875748
references: J Pharmacol Exp Ther. 2002 Oct;303(1):238-46
references: 12235257
references: Eur J Cancer. 1998 Jul;34(8):1274-81
references: 9849491
references: Cancer Res. 1980 Sep;40(9):3118-29
references: 7000337
references: Mol Cancer. 2006 May 18;5:20
references: 16709241
references: J Toxicol Sci. 2006 Aug;31(3):265-85
references: 16960436
references: Mol Cancer Ther. 2008 May;7(5):1033-43
references: 18483293
references: Bioorg Med Chem. 2000 Jul;8(7):1697-706
references: 10976516
references: Invest New Drugs. 2000 Nov;18(4):343-54
references: 11081570
references: Biochem Soc Trans. 2003 Dec;31(Pt 6):1203-8
references: 14641026
references: Tumori. 2001 Nov-Dec;87(6):364-71
references: 11989587
references: Clin Cancer Res. 2003 Oct 15;9(13):4735-42
references: 14581344
references: Anticancer Drugs. 2009 Apr;20(4):217-29
references: 19247178
references: Mol Cancer Ther. 2010 Apr;9(4):869-82
references: 20354119
references: Curr Protoc Toxicol. 2002 Feb;Chapter 4:Unit4.7
references: 20945299
references: Biochim Biophys Acta. 1969 Jan 7;171(1):128-37
references: 4884138
references: Oncogene. 2007 May 14;26(22):3291-310
references: 17496923
references: J Pharmacol Exp Ther. 2005 Jun;313(3):1011-6
references: 15687373
references: Recent Results Cancer Res. 1976;(57):33-41
references: 1013510
references: Biochem Pharmacol. 2005 Aug 15;70(4):511-9
references: 15982640
references: J Pharmacol Exp Ther. 2006 Feb;316(2):572-80
references: 16223870
references: Breast Cancer Res Treat. 2012 May;133(1):217-26
references: 21915635
references: Cell. 2007 Nov 30;131(5):1018
references: 18045542
references: Bioorg Med Chem Lett. 2009 Sep 15;19(18):5505-9
references: 19665377
references: Mol Pharmacol. 1999 Oct;56(4):693-704
references: 10496951
references: Chem Biol Drug Des. 2011 May;77(5):309-18
references: 21294849
references: Br J Cancer. 2002 May 6;86(9):1367-72
references: 11986765
references: J Clin Invest. 1999 Aug;104(3):263-9
references: 10430607
references: Ann Oncol. 2009 Feb;20(2):265-71
references: 18765464
references: Invest New Drugs. 2011 Oct;29(5):833-45
references: 20428924
references: Oncol Rep. 2004 Jul;12(1):19-23
references: 15201953
references: J Clin Oncol. 2006 Sep 1;24(25):4051-3
references: 16943521
references: J Clin Oncol. 1998 Sep;16(9):2977-85
references: 9738566
references: Cell Mol Life Sci. 2009 Mar;66(5):788-99
references: 18979208
references: J Biol Chem. 2004 Feb 27;279(9):7598-605
references: 14665630